Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06122610 · ClinicalTrials.gov registry record · Phase 1
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
A Phase 1 study of Neuroendocrine Tumors and Somatostatin Receptor-positive Neuroendocrine Tumor, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06122610 is a Phase 1 study of Neuroendocrine Tumors and Somatostatin Receptor-positive Neuroendocrine Tumor that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 10 participants, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06122610, a Phase 1 study of Neuroendocrine Tumors and Somatostatin Receptor-positive Neuroendocrine Tumor, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans
Conditions Studied
Interventions
- DEVICE Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)
- DEVICE Photon Emission Tomography / CT (PET/CT)
- DRUG 64Cu-Dotatate
- DRUG 177Lu-Dotatate
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-03-07 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06122610
The ClinicalTrials.gov registry entry for NCT06122610 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (94% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 4 interventions - of which Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT) is the first listed.
NCT06122610 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06122610 about?
NCT06122610 is a clinical study titled "Using Novel Imaging to More Safely Treat Neuroendocrine Tumors". The goal of this research is to determine if DetectnetTM PET/CT can be used to make Lutathera therapy safer for patients with neuroendocrine cancer. Participants will: * Complete two phases involving 6 visits * Undergo additional research PET/CT, and possibly SPECT/CT scans
What is the current status of trial NCT06122610?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-03-07. Estimated completion is 2026-06.
What conditions does trial NCT06122610 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor.
What interventions are being tested in trial NCT06122610?
The interventions under investigation include: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT) (DEVICE), Photon Emission Tomography / CT (PET/CT) (DEVICE), 64Cu-Dotatate (DRUG), 177Lu-Dotatate (DRUG).
Who is sponsoring clinical trial NCT06122610?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06122610 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
RECRUITING · Phase 1
-
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Neuroendocrine Tumors
All registered trials for this condition
Somatostatin Receptor-positive Neuroendocrine Tumor
All registered trials for this condition
Wisconsin
All trials with a study site in Wisconsin
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.